AxoGen (AXGN) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Axogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:01 PM ESTFourth Quarter Revenue of $23.4 million, representing 38% growth over prior yearFull Year 2018 Revenue of $83.9 million, representing 39% growth over prior year
ALACHUA, Fla., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
Fourth Quarter 2018 Financial Results and Recent Business Highlights
Revenue of $23.4 million, up 38% compared to fourth quarter 2017 revenue of $17.0... More